1. Home
  2. Angel / Venture

Category: Pharma and Healthcare

LBO France holds EUR 155m final close for Digital Health 2

LBO France has held a EUR 155m final close for Digital Health 2, a fund dedicated to French and western European digital health SMEs.

LBO France boosts digital health strategy with €155m sophomore fund close

LBO France's digital health venture strategy has received a huge boost through the €155m final close of its second fund. The post LBO France boosts digital health strategy with €155m sophomore fund close first appeared

Sofinnova holds EUR 472m final close for Capital X

France-headquartered Sofinnova Partners has held a EUR 472m final close for Sofinnova Capital X, which will focus on early-stage healthcare venture investments.

Vistria sells hospice, palliative care specialist Agape to Ridgemont Equity Partners

Chicago-based Vistria Group has sold hospice and palliative care provider Agape Care Group to Ridgemont Equity Partners. Agape offers full end-of-life care in patient homes and healthcare facilities throughout South Carolina, and recently expanded into Georgia

HIG settles mental health billing fraud case with almost $20m payment

Private equity major HIG Capital has paid almost $20m to settle a lawsuit claiming its mental health company portfolio business South Bay fraudulently billed Medicaid for services provided by unlicensed, unqualified, and improperly supervised staff.

Permira exits medical device maker LSNE after European market debut

Private equity major Permira has exited medical device maker Lyophilization Services of New England (LSNE) to PCI Pharma Services. The post Permira exits medical device maker LSNE after European market debut first appeared on AltAssets

Vendis puts Sylphar on the market

Vendis Capital has hired Rothschild to advise on the sale of Sylphar, a Belgium-based over-the-counter (OTC) health products and cosmetics specialist, two sources familiar with the situation said.

We use cookies to offer you a better browsing experience. If you continue to use this site, you consent to our use of cookies.
We use cookies to offer you a better browsing experience. If you continue to use this site, you consent to our use of cookies.